These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 23726594)
1. The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome. Banasik M; Boratyńska M; Kościelska-Kasprzak K; Mazanowska O; Krajewska M; Zabińska M; Bartoszek D; Myszka M; Nowakowska B; Dawiskiba T; Lepiesza A; Chudoba P; Klinger M Transplant Proc; 2013 May; 45(4):1449-52. PubMed ID: 23726594 [TBL] [Abstract][Full Text] [Related]
2. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion. Solgi G; Pourmand G; Mehrsai A; Taherimahmoudi M; Nicknam MH; Ebrahimi Rad MR; Seraji A; Asadpoor A; Ansaripor B; Nikbin B; Amirzargar A Iran J Immunol; 2010 Mar; 7(1):18-29. PubMed ID: 20371916 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902 [TBL] [Abstract][Full Text] [Related]
6. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Li X; Ishida H; Yamaguchi Y; Tanabe K Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618 [TBL] [Abstract][Full Text] [Related]
7. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487 [TBL] [Abstract][Full Text] [Related]
8. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Lee PC; Ozawa M Clin Transpl; 2007; ():219-26. PubMed ID: 18642453 [TBL] [Abstract][Full Text] [Related]
9. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Higgins R; Lowe D; Hathaway M; Williams C; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Daga S; Edey M; Zehnder D; Briggs D Transplantation; 2011 Oct; 92(8):900-6. PubMed ID: 21968524 [TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE; Gralla J; Chan L; Wiseman AC Clin Transpl; 2011; ():359-64. PubMed ID: 22755431 [TBL] [Abstract][Full Text] [Related]